|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Alexion Pharmaceuticals Inc., of Cheshire, Conn., said results of its Phase III trial of pexelizumab were published in the May 19, 2004, issue of the Journal of the American Medical Association. A summary of data from the 3,099-patient study, which examined the terminal complement inhibitor's efficacy in patients undergoing coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass, were first reported last fall at the American Heart Association meeting in Orlando, Fla. It showed that pexelizumab might beneficially impact inflammation and ischemia/reperfusion, thereby reducing the frequency and severity of myocardial infarction following CABG surgery. (See ...
Related newspaper, magazine, and journal articles:
|
|
Article: Cel-Sci Acquisition Inc., of the British Virgin Islands, ...
BIOWORLD Today;
August 23, 1999 ;
700+ words
... ... Corp.'s legal counsel. (See BioWorld Today, Aug. 20, 1999, p. 1 ... Bristol-Myers Squibb Co., of New York, as part of its license and ... 87 million in cash. (See BioWorld Today, Aug. 3, 1999, p. 1 ...
|
|